Skip to main
HQY

HealthEquity (HQY) Stock Forecast & Price Target

HealthEquity (HQY) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 64%
Hold 0%
Sell 0%
Strong Sell 9%

Bulls say

HealthEquity is a leading provider of healthcare savings and spending solutions with a strong focus on personalized benefits and investment advice. The company's early innings are reflective of its potential for growth, with only 10,000 current HSA account holders in its marketplace and a potential $10 million in new revenue. The company's investment in automation and AI is expected to drive further gross margin expansion, and its leadership team's focus on digitizing the platform holds the potential for significant growth and margin expansion in the future. With a strong balance sheet and liquidity, HealthEquity is also positioned for inorganic growth opportunities in the fragmented HSA market. The regulatory landscape is also improving for potential TAM expansion, and the company is positioned to achieve its long-term targets of a $300 billion market with >30% revenue share. Management's focus on expanding the company's digital platform, increasing win rates, new marketplace revenue, TAM expansion and inorganic growth opportunities are all factors that contribute to a positive outlook for this stock. Additionally, the company's strong financials, with consistent account growth, improved margins, and a discounted trading level, support an Outperform rating and price target of $110.

Bears say

HealthEquity is facing a number of risks, such as declining interest rates, increasing competition, and potential changes in the regulatory environment. Additionally, there is growing popularity of alternative payment methods and a slow post-pandemic recovery which could impact the company's performance. HQY has a Nominating, Governance, and Corporate Sustainability Committee and encourages sustainability through its commuter benefits and volunteering programs. However, the company still faces risks related to cybersecurity attacks and potential fraud. While the company has shown strong results in terms of HSA growth and cost discipline, it is important to monitor the ongoing litigation and potential regulatory changes that could impact its business. Overall, these risks contribute to the negative outlook on HealthEquity's stock.

HealthEquity (HQY) has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 64% recommend Buy, 0% suggest Holding, 0% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of HealthEquity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HealthEquity (HQY) Forecast

Analysts have given HealthEquity (HQY) a Buy based on their latest research and market trends.

According to 11 analysts, HealthEquity (HQY) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $114.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $114.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HealthEquity (HQY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.